Acurx Pharmaceuticals (NasdaqCM: ACXP) announced completing a stock purchase agreement with a single institutional investor in May 2023, offering a mix of shares and warrants to provide ACXP with $4.0 million before fees and offering expenses at $3 per share. Ironically, shares traded lower on the deal’s announcement. But that’s not necessarily bad news. The […]
